Giovanni Barosi

TL;DR: It is concluded that a low JAK2V617F allele burden at diagnosis is preferentially associated with a myelodepletive rather than myeloproliferative phenotype and represents an independent factor associated with shortened survival in patients with PMF.

TL;DR: Pomalidomide therapy at 0.5 or 2 mg/d with or without an abbreviated course of prednisone is well tolerated in patients with myelofibrosis and active in the treatment of anemia.

TL;DR: The Italian Society of Hematology appointed a panel of experts to produce clinical practice-guidelines for the management of iron overload in thalassemia major and related disorders, and the resulting recommendations advise about which examination to carry out in order to planIron chelation therapy, when to start iron chelation, which iron chelator to choose in regularly transfused patients, how to monitor iron chelated therapy, and when and how to switch standard therapy.

TL;DR: MK hyperplasia in IMF is likely a consequence of both the increased ability of IMF progenitor cells to generate MKs and a decreased rate of MK apoptosis, which contribute to the development of many pathological epiphenomena associated with IMF.

TL;DR: Among the ‘classic’ BCR/ABL-negative chronic myeloproliferative disorders, primary myelofibrosis (PMF) is associated with a substantial life-expectancy reduction and the importance of higher leukocyte counts in thrombosis development has been recently pointed out in ET and PV, where a role for mutated JAK2 allele burden has been noted.